In addition to codrivers in NSCLC, MET mutations are generally thought to be mutually exclusive with mutations in other major lung cancer drivers and have not been shown to be associated with acquired resistance to EGFR-TKI therapy [43]. This evidence concerns the gene EGFR and lung cancer.